National
Madeleine Albright passes away at 84
Trailblazing secretary of state extended benefits to domestic partners
Madeleine Albright, the first woman to serve as a U.S. secretary of state, has died at 84 after battling cancer.
Albright was nominated on Dec. 5, 1996, by then-President Clinton to become the 64th secretary of state after serving as the U.S. ambassador to the U.N.
She was confirmed by the U.S. Senate on Jan. 22, 1997, and sworn in the next day. Albright served as secretary of state for four years, ending her service on Jan. 20, 2001, upon the inauguration of former President George W. Bush.
Albright had a long and distinguished career as a U.S. envoy.
As secretary of state, she was the first State Department head to allow domestic partners, including same-sex partners, to accompany overseas staff, and require that foreign governments officially accredit them. In 1999, the secretary advocated that Clinton go ahead with his decision to appoint the first openly gay U.S. ambassador, James Hormel, as a recess appointment, as the U.S. ambassador to Luxembourg.
In her role as secretary of state, Albright was a trailblazer that set an example that would be followed by two other prominent American women, former Secretaries of State Condoleezza Rice and Hillary Clinton.
Speaking with CNN during a 2005 interview, Albright acknowledged her role as a trailblazer and often spoke of the challenges of being the first woman to lead the State Department.
“I think that there were real questions as to … whether a woman could be secretary of state. And not just in terms of dealing with the issues, but in terms of dealing with the people, especially in hierarchical societies … I found, actually, that I could do that,” she told CNN. “And people, I think, now can understand that is perfectly possible for a woman to be secretary of state, and I am delighted that there is second one,” a reference to Rice.
CNN also noted Albright’s trademark personal accessories for which she was famous. Throughout her career, Albright was known for wearing brooches or decorative pins to convey her foreign policy messages.
When she found out that the Russians had bugged the State Department, she wore a large bug pin when she next met with them. When Saddam Hussein referred to Albright as a snake, she took to wearing a gold snake pin; when she was called a witch, she proudly brandished a miniature broom.
When she slammed as “completely un-American” then-acting U.S. Citizenship and Immigration Services Director Ken Cuccinelli’s suggestion that only immigrants who can “stand on their own two feet” are welcome in the U.S., Albright wore a Statue of Liberty pin.
After her tenure as secretary of state, she went on to publish seven New York Times bestsellers including her 2003 autobiography “Madam Secretary”. Albright received the Presidential Medal of Freedom, the nation’s highest civilian honor, from then-President Obama on May 29, 2012.
She also was chair of Albright Stonebridge Group, she founded in 2009, part of Dentons Global Advisors, and served as a professor in the practice of diplomacy at the Georgetown University School of Foreign Service.
Albright was born Marie Jean “Madlenka” Korbel on May 15, 1937, in Prague. Her father, Josef, was a member of the Czechoslovak Foreign Service and served as press attaché in Belgrade, Yugoslavia, and later became ambassador to Yugoslavia.
After the Communist coup in 1948, the family immigrated to Denver. Albright Americanized her name to Madeleine, became a U.S. citizen in 1957, and earned a B.A. in political science with honors from Wellesley College in 1959. She earned the Ph.D. in Public Law and Government at Columbia University in 1976.
Albright served as chief legislative assistant to U.S. Sen. Edmund Muskie (D-Maine) from 1976-1978. From 1978-1981, she served as a staff member in the White House under President Carter and on the National Security Council under then-National Security Adviser Zbigniew Brzezinski.
In 1982 she was appointed Research Professor of International Affairs at Georgetown University’s School of Foreign Service and director of its Women in Foreign Service Program. In 1993 she was appointed ambassador to the U.N. by Clinton and served in the position until her appointment as secretary of state in 1996.
One writer, based in D.C., described Albright’s life as “Along the way, the Czech girl — whose parents brought her to the U.S. as a refugee from Communist rule, and who only much later discovered that members of her family died in the Holocaust — became a role model and a pathbreaker for professional women and for women in top government positions.”
President Biden traveling aboard Air Force One en route to Brussels for an emergency NATO meeting over the crisis in Ukraine on Wednesday issued a statement remembering Albright:
“Madeleine Albright was a force.
Hers were the hands that turned the tide of history.
As a young girl, she found a home in the United States—after her family fled their home country of Czechoslovakia during World War II, and the Iron Curtain came down across Central and Eastern Europe. Her father, a diplomat, was marked for death by the Soviet regime. She spent the rest of her days defending freedom around the world and lifting up those who suffered under repression.
She was an immigrant fleeing persecution. A refugee in need of safe haven. And like so many before her—and after—she was proudly American.
To make this country that she loved even better—she defied convention and broke barriers again and again. As the devoted mother of three beloved daughters, she worked tirelessly raising them while earned her doctorate degree and started her career. She took her talents first to the Senate as a staffer for Sen. Edmund Muskie, followed by the National Security Council under President Carter. And then to the United Nations where she served as U.S. Ambassador, and ultimately, made history as our first woman Secretary of State, appointed by President Clinton.
A scholar, teacher, bestselling author and later accomplished businesswoman, Secretary Albright continued to advise presidents and members of Congress with matchless skill and diplomatic acumen. In every role, she used her fierce intellect and sharp wit—and often her unmatched collection of pins—to advance America’s national security and promote peace around the world. America had no more committed champion of democracy and human rights than Secretary Albright, who knew personally and wrote powerfully of the perils of autocracy.
Working with Secretary Albright during the 1990s was among the highlights of my career in the United States Senate during my tenure on the Foreign Relations Committee. As the world redefined itself in the wake of the Cold War, we were partners and friends working to welcome newly liberated democracies into NATO and confront the horrors of genocide in the Balkans.
When I think of Madeleine, I will always remember her fervent faith that America is the indispensable nation.
In the years after she left government, Albright never stepped away from that belief. As the chairman of the National Democratic Institute for over two decades, and through other organizations she advised, she continued to champion democratic principles as vitally important to America’s interests in freedom, prosperity and security.
She continued to mentor and nurture new generations of foreign policy experts at Georgetown University, the Korbel Center for International Studies at the University of Denver, named after her father, and beyond. As always, she shared her insight and wisdom widely, but she was especially dedicated to supporting the next generation of women leaders, including through the establishment of the Albright Institute for Global Affairs at Wellesley College.
Madeleine was always a force for goodness, grace and decency—and for freedom.
Jill and I will miss her dearly and send our love and prayers to her daughters, Alice, Anne and Katie, her sister Kathy, her brother John, her six grandchildren and her nephews and grandniece.”
Federal Government
Holiday week brings setbacks for Trump-Vance trans agenda
Federal courts begin to deliver end-of-year responses to lawsuits involving federal transgender healthcare policy.
While many Americans took the week of Christmas to rest and relax, LGBTQ politics in the U.S. continued to shift. This week’s short recap of federal updates highlights two major blows to the Trump-Vance administration’s efforts to restrict gender-affirming care for minors.
19 states sue RFK Jr. to end gender-affirming care ban
New York Attorney General Letitia James announced on Tuesday that the NYAG’s office, along with 18 other states (and the District of Columbia), filed a lawsuit to stop U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. from restricting gender-affirming care for minors.
In the press release, Attorney General James stressed that the push by the Trump-Vance administration’s crusade against the transgender community — specifically transgender youth — is a “clear overreach by the federal government” and relies on conservative and medically unvalidated practices to “punish providers who adhere to well-established, evidence-based care” that support gender-affirming care.
“At the core of this so-called declaration are real people: young people who need care, parents trying to support their children, and doctors who are simply following the best medical evidence available,” said Attorney General James. “Secretary Kennedy cannot unilaterally change medical standards by posting a document online, and no one should lose access to medically necessary health care because their federal government tried to interfere in decisions that belong in doctors’ offices. My office will always stand up for New Yorkers’ health, dignity, and right to make medical decisions free from intimidation.”
The lawsuit is a direct response to HHS’ Dec. 18 announcement that it will pursue regulatory changes that would make gender-affirming health care for transgender children more difficult, if not impossible, to access. It would also restrict federal funding for any hospital that does not comply with the directive. KFF, an independent source for health policy research, polling, and journalism, found that in 2023 federal funding covered nearly 45% of total spending on hospital care in the U.S.
The HHS directive stems directly from President Donald Trump’s Jan. 28 Executive Order, Protecting Children From Chemical and Surgical Mutilation, which formally establishes U.S. opposition to gender-affirming care and pledges to end federal funding for such treatments.
The American Medical Association, the nation’s largest and most influential physician organization, has repeatedly opposed measures like the one pushed by President Trump’s administration that restrict access to trans health care.
“The AMA supports public and private health insurance coverage for treatment of gender dysphoria and opposes the denial of health insurance based on sexual orientation or gender identity,” a statement on the AMA’s website reads. “Improving access to gender-affirming care is an important means of improving health outcomes for the transgender population.”
The lawsuit also names Oregon, Washington, California, Colorado, Connecticut, Delaware, the District of Columbia, Illinois, Maine, Maryland, Massachusetts, Michigan, Minnesota, New Mexico, Pennsylvania, Rhode Island, Vermont, and Wisconsin as having joined New York in the push against restricting gender-affirming care.
At the HHS news conference last Thursday, Jim O’Neill, deputy secretary of the department, asserted, “Men are men. Men can never become women. Women are women. Women can never become men.”
DOJ stopped from gaining health care records of trans youth
U.S. District Judge Cathy Bissoon blocked an attempt by the Department of Justice (DOJ) to gain “personally identifiable information about those minor transgender patients” from the University of Pittsburgh Medical Center (UPMC), saying the DOJ’s efforts “fly in the face of the Supreme Court.”
Journalist Chris Geidner originally reported the news on Dec. 25, highlighting that the Western District of Pennsylvania judge’s decision is a major blow to the Trump-Vance administration’s agenda to curtail transgender rights.
“[T]his Court joins the others in finding that the government’s demand for deeply private and personal patient information carries more than a whiff of ill intent,” Bissoon wrote in her ruling. “This is apparent from its rhetoric.”
Bissoon cited the DOJ’s “incendiary characterization” of trans youth care on the DOJ website as proof, which calls the practice politically motivated rather than medically sound and seeks to “…mutilate children in the service of a warped ideology.” This is despite the fact that a majority of gender-affirming care has nothing to do with surgery.
In United States v. Skrmetti, the Supreme Court ruled along party lines that states — namely Tennessee — have the right to pass legislation that can prohibit certain medical treatments for transgender minors, saying the law is not subject to heightened scrutiny under the Equal Protection Clause of the Fourteenth Amendment because it does not involve suspect categories like race, national origin, alienage, and religion, which would require the government to show the law serves a compelling interest and is narrowly tailored, sending decision-making power back to the states.
“The government cannot pick and choose the aspects of Skrmetti to honor, and which to ignore,” Judge Bissoon added.
The government argued unsuccessfully that the parents of the children whose records would have been made available to the DOJ “lacked standing” because the subpoena was directed at UPMC and that they did not respond in a timely manner. Bissoon rejected the timeliness argument in particular as “disingenuous.”
Bissoon, who was nominated to the bench by then-President Obama, is at least the fourth judge to reject the DOJ’s attempted intrusion into the health care of trans youth according to Geidner.
A Wider Bridge on Friday announced it will shut down at the end of the month.
The group that “mobilizes the LGBTQ community to fight antisemitism and support Israel and its LGBTQ community” in a letter to supporters said financial challenges prompted the decision.
“After 15 years of building bridges between LGBTQ communities in North America and Israel, A Wider Bridge has made the difficult decision to wind down operations as of Dec. 31, 2025,” it reads.
“This decision comes after challenging financial realities despite our best efforts to secure sustainable funding. We deeply appreciate our supporters and partners who made this work possible.”
Arthur Slepian founded A Wider Bridge in 2010.
The organization in 2016 organized a reception at the National LGBTQ Task Force’s Creating Change Conference in Chicago that was to have featured to Israeli activists. More than 200 people who protested against A Wider Bridge forced the event’s cancellation.
A Wider Bridge in 2024 urged the Capital Pride Alliance and other Pride organizers to ensure Jewish people can safely participate in their events in response to an increase in antisemitic attacks after Hamas militants attacked Israel on Oct. 7, 2023.
The Jewish Telegraphic Agency reported authorities in Vermont late last year charged Ethan Felson, who was A Wider Bridge’s then-executive director, with lewd and lascivious conduct after alleged sexual misconduct against a museum employee. Rabbi Denise Eger succeeded Felson as A Wider Bridge’s interim executive director.
A Wider Bridge in June honored U.S. Rep. Debbie Wasserman Schultz (D-Fla.) at its Pride event that took place at the Capital Jewish Museum in D.C. The event took place 15 days after a gunman killed two Israeli Embassy employees — Yaron Lischinsky and Sarah Milgrim — as they were leaving an event at the museum.
“Though we are winding down, this is not a time to back down. We recognize the deep importance of our mission and work amid attacks on Jewish people and LGBTQ people – and LGBTQ Jews at the intersection,” said A Wider Bridge in its letter. “Our board members remain committed to showing up in their individual capacities to represent queer Jews across diverse spaces — and we know our partners and supporters will continue to do the same.”
Editor’s note: Washington Blade International News Editor Michael K. Lavers traveled to Israel and Palestine with A Wider Bridge in 2016.
The White House
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
President made announcement on Friday
President Donald Trump met with leaders from some of the world’s largest pharmaceutical companies at the White House on Friday to announce his new “Trump Rx” plan and outline efforts to reduce medication costs for Americans.
During the roughly 47-minute meeting in the Roosevelt Room, Trump detailed his administration’s efforts to cut prescription drug prices and make medications more affordable for U.S. patients.
“Starting next year, American drug prices will come down fast, furious, and will soon be among the lowest in the developed world,” Trump said during the meeting. “For decades, Americans have been forced to pay the highest prices in the world for prescription drugs by far … We will get the lowest price of anyone in the world.”
Trump signed an executive order in May directing his administration “to do everything in its power to slash prescription drug prices for Americans while getting other countries to pay more.”
“This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit,” he added.
Several pharmaceutical executives stood behind the president during the announcement, including Sanofi CEO Paul Hudson, Novartis CEO Vas Narasimhan, Genentech CEO Ashley Magargee, Boehringer Ingelheim (USA) CEO Jean-Michel Boers, Gilead Sciences CEO Dan O’Day, Bristol Myers Squibb General Counsel Cari Gallman, GSK CEO Emma Walmsley, Merck CEO Robert Davis, and Amgen Executive Vice President Peter Griffith.
Also in attendance were Health and Human Services Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and Food and Drug Administration Commissioner Marty Makary.
Under the Trump Rx plan, the administration outlined a series of proposed drug price changes across multiple companies and therapeutic areas. Among them were reductions for Amgen’s cholesterol-lowering drug repatha from $573 to $239; Bristol Myers Squibb’s HIV medication reyataz from $1,449 to $217; Boehringer Ingelheim’s type 2 diabetes medication jentadueto from $525 to $55; Genentech’s flu medication xofluza from $168 to $50; and Gilead Sciences’ hepatitis C medication epclusa from $24,920 to $2,425.
Additional reductions included several GSK inhalers — such as the asthma inhaler advair diskus 500/50, from $265 to $89 — Merck’s diabetes medication januvia from $330 to $100, Novartis’ multiple sclerosis medication mayzent from $9,987 to $1,137, and Sanofi’s blood thinner plavix from $756 to $16. Sanofi insulin products would also be capped at $35 per month’s supply.
These prices, however, would only be available to patients who purchase medications directly through TrumpRx. According to the program’s website, TrumpRx “connects patients directly with the best prices, increasing transparency, and cutting out costly third-party markups.”
Kennedy spoke after Trump, thanking the president for efforts to lower pharmaceutical costs in the U.S., where evidence has shown that drug prices — including both brand-name and generic medications — are nearly 2.78 times higher than prices in comparable countries. According to the Pharmaceutical Research and Manufacturers of America, roughly half of every dollar spent on brand-name drugs goes to entities that play no role in their research, development, or manufacturing.
“This is affordability in action,” Kennedy said. “We are reversing that trend and making sure that Americans can afford to get the life-saving solutions.”
Gilead CEO Dan O’Day also spoke about how the restructuring of drug costs under TrumpRx, combined with emerging technologies, could help reduce HIV transmission — a virus that, if untreated, can progress to AIDS. The LGBTQ community remains disproportionately affected by HIV.
“Thank you, Mr. President — you and the administration,” O’Day said. “I think this objective of achieving the commitment to affordability and future innovation is extraordinary … We just recently launched a new medicine that’s only given twice a year to prevent HIV, and we’re working with Secretary Kennedy and his entire team, as well as the State Department, as a part of your strategy to support ending the epidemic during your term.
“I’ve never been more optimistic about the innovation that exists across these companies and the impact this could have on America’s health and economy,” he added.
Trump interjected, asking, “And that’s working well with HIV?”
“Yes,” O’Day replied.
“It’s a big event,” Trump said.
“It literally prevents HIV almost 100 percent given twice a year,” O’Day responded.
A similar anti-HIV medication is currently prescribed more than injectable form mentioned by O’Day. PrEP, is a medication regimen proven to significantly reduce HIV infection rates for people at high risk. Without insurance, brand-name Truvada can cost roughly $2,000 per month, while a generic version costs about $60 per month.
Even when medication prices are reduced, PrEP access carries additional costs, including clinic and laboratory fees, office visits, required HIV and sexually transmitted infection testing, adherence services and counseling, and outreach to potentially eligible patients and providers.
According to a 2022 study, the annual total cost per person for PrEP — including medication and required clinical and laboratory monitoring — is approximately $12,000 to $13,000 per year.
The TrumpRx federal platform website is now live at TrumpRx.gov, but the program is not slated to begin offering reduced drug prices until January.
How to cope when a partner gives you the silent treatment
Out actor talks lead role in ‘Fiddler on the Roof’
This gay author sees dead people
Holiday week brings setbacks for Trump-Vance trans agenda
Your guide to D.C.’s queer New Year’s Eve parties
Your guide to D.C.’s queer New Year’s Eve parties
Holiday week brings setbacks for Trump-Vance trans agenda
Out actor talks lead role in ‘Fiddler on the Roof’
This gay author sees dead people
